BRAF and cancer: In addition, we performed targeted-panel sequencing covering the coding sequences of 410 cancer-associated target genes exemplarily on Mel-DCC-11 (parental, sensitive to BRAF inhibitor) and its Vemurafenib-resistant derivative Mel-DCC-11-R) to identify resistance-causing mutations.